使用C5阻滞剂LFG316抑制补体在重症新型冠状病毒肺炎中的作用 - Suppr

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19.

作者信息

Zelek Wioleta M, Cole Jade, Ponsford Mark J, Harrison Richard A, Schroeder Ben E, Webb Nicholas, Jolles Stephen, Fegan Christopher, Morgan Matt, Wise Matt P, Morgan B Paul

机构信息

Cardiff University, Cardiff, United Kingdom.

University Hospital of Wales, Cardiff, United Kingdom and.

出版信息

Am J Respir Crit Care Med. 2020 Nov 1;202(9):1304-1308. doi: 10.1164/rccm.202007-2778LE.

DOI:10.1164/rccm.202007-2778LE

PMID:32897730

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7605181/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86f0/7605181/f5f1bdb8d50e/rccm.202007-2778LEf1.jpg

相似文献

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19.

Am J Respir Crit Care Med. 2020 Nov 1;202(9):1304-1308. doi: 10.1164/rccm.202007-2778LE.

Terminal complement inhibition dampens the inflammation during COVID-19.

Br J Haematol. 2020 Aug;190(3):e141-e143. doi: 10.1111/bjh.16916. Epub 2020 Jun 28.

Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).

Ann Intern Med. 2020 Oct 20;173(8):670-672. doi: 10.7326/M20-1550. Epub 2020 May 12.

The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.

Ann Intern Med. 2020 Oct 20;173(8):662-663. doi: 10.7326/M20-5041. Epub 2020 Jul 16.

A Word of Caution in the Use of Hydroxychloroquine in the Elderly COVID-19 Population.

Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):374-375. doi: 10.1097/APO.0000000000000314.

Curing COVID-19.

Lancet Infect Dis. 2020 Oct;20(10):1101. doi: 10.1016/S1473-3099(20)30706-4. Epub 2020 Sep 10.

Meta-analysis of Effect of Statins in Patients with COVID-19.

Am J Cardiol. 2020 Nov 1;134:153-155. doi: 10.1016/j.amjcard.2020.08.004. Epub 2020 Aug 12.

Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective.

Eur Respir J. 2020 May 7;55(5). doi: 10.1183/13993003.01009-2020. Print 2020 May.

Asthma and COVID-19: Is asthma a risk factor for severe outcomes?

Allergy. 2020 Jul;75(7):1543-1545. doi: 10.1111/all.14348.

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.

Am J Kidney Dis. 2020 Sep;76(3):303-305. doi: 10.1053/j.ajkd.2020.05.002. Epub 2020 May 29.

引用本文的文献

Transcriptomic analysis of differential expression between surviving and nonsurviving patients infected by the SARS-CoV-2 Delta variant.

Sci Rep. 2025 May 15;15(1):16844. doi: 10.1038/s41598-025-00280-3.

Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: Potential targets for nafamostat mesilate.

J Intensive Med. 2024 Apr 10;4(4):453-467. doi: 10.1016/j.jointm.2024.02.003. eCollection 2024 Oct.

The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges.

Thromb Update. 2022 Aug;8:100117. doi: 10.1016/j.tru.2022.100117. Epub 2022 Jul 9.

Emerging role of complement in COVID-19 and other respiratory virus diseases.

Cell Mol Life Sci. 2024 Feb 18;81(1):94. doi: 10.1007/s00018-024-05157-8.

In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway.

Front Immunol. 2023 Jun 29;14:1180833. doi: 10.3389/fimmu.2023.1180833. eCollection 2023.

Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients.

Pathol Res Pract. 2023 Jul;247:154519. doi: 10.1016/j.prp.2023.154519. Epub 2023 May 8.

Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.

Immunobiology. 2023 May;228(3):152393. doi: 10.1016/j.imbio.2023.152393. Epub 2023 May 11.

Levels of Complement Components in Children With Acute COVID-19 or Multisystem Inflammatory Syndrome.

JAMA Netw Open. 2023 Mar 1;6(3):e231713. doi: 10.1001/jamanetworkopen.2023.1713.

Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against type b.

Front Immunol. 2022 Dec 12;13:1020580. doi: 10.3389/fimmu.2022.1020580. eCollection 2022.

Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review.

World J Exp Med. 2022 Jul 20;12(4):53-67. doi: 10.5493/wjem.v12.i4.53.

本文引用的文献

Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.

N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.

Clin Immunol. 2020 Jun;215:108450. doi: 10.1016/j.clim.2020.108450. Epub 2020 Apr 29.

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.

Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4040-4047. doi: 10.26355/eurrev_202004_20875.

Complement as a target in COVID-19?

Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23.

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.

Transl Res. 2020 Jun;220:1-13. doi: 10.1016/j.trsl.2020.04.007. Epub 2020 Apr 15.

Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction.

Front Immunol. 2019 Mar 21;10:543. doi: 10.3389/fimmu.2019.00543. eCollection 2019.

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.

mBio. 2018 Oct 9;9(5):e01753-18. doi: 10.1128/mBio.01753-18.

Complement, a target for therapy in inflammatory and degenerative diseases.

Nat Rev Drug Discov. 2015 Dec;14(12):857-77. doi: 10.1038/nrd4657. Epub 2015 Oct 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献